- Home
- DLTH vs KZIA Comparison
DLTH vs KZIA Comparison
Compare DLTH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLTH | KZIA |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 100.8M |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DLTH | KZIA |
|---|---|---|
| Price | $3.60 | $12.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $19.50 |
| AVG Volume (30 Days) | 102.1K | ★ 214.5K |
| Earning Date | 06-04-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.66 | $3.05 |
| 52 Week High | $4.66 | $17.40 |
Technical Indicators
Market Signals| Indicator | DLTH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 72.34 |
| Support Level | $3.39 | $5.85 |
| Resistance Level | $4.66 | $14.42 |
| Average True Range (ATR) | 0.19 | 1.25 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 86.52 | 91.54 |
Price Performance
Historical ComparisonAbout DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.